Actual results and the timing of events could differ materially from those anticipated in the
forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in
clinical testing; Alder's ability to conduct
clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the
clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing
on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report
on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC)
on February 26, 2018, and is available
on the SEC's website at www.sec.gov.
«It is exciting to be directly involved in creating an innovative
clinical trial infrastructure that will yield important efficacy and safety data
on novel asthma interventions,» says Dr. Jain, «I look
forward to participating in this work and seeing how it directly impacts asthma patients.»
As we produce more human - relevant data with our Organ - Chips, we look
forward to making a positive impact
on informing R&D decisions, reducing drug candidate attrition in human
clinical trials, and helping to deliver better and safer medicines to patients.»
«This
clinical trial is an important step
forward in identifying and understanding perhaps underused weapons in the war
on childhood cancer,» said Dr. Robin Ganzert, American Humane Association's president and CEO.